RxDoctor Payments DataLook up a doctor →

Sanjaya Gupta, MD

Clinical Cardiac Electrophysiology · Kansas City, MONPI 1700904182

Payments from drug & device makers

$1,319,580in general payments, 2019–2025

Across 553 payments — averaging $2386.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$443K
  • Boston Scientific$408K
  • Abbott$260K
  • Cordis US CORP.$104K
  • ZOLL Respicardia, Inc.$79K
  • E.r. Squibb & Sons, L.L.C.$18K
  • plus $8K from 11 others

What the payments were for

  • Consulting fees$29,9259%
  • Speaking & faculty fees$237,31175%
  • Travel & lodging$32,29610%
  • Food & beverage$16,8265%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,319,580 in reported general payments places this provider in the 95th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$264,222
Medicare patients
1,750
Services billed
4,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban509$554,978
XareltoRivaroxaban108$113,706
EntrestoSacubitril/Valsartan35$45,891
JardianceEmpagliflozin33$35,514
Dofetilide127$17,149
FarxigaDapagliflozin Propanediol18$15,802
Flecainide Acetate159$9,560
Diltiazem 24hr Er (Cd)Diltiazem Hcl154$3,790
Metoprolol Succinate251$2,717
Prasugrel Hcl11$2,609
Atorvastatin Calcium191$2,111
Carvedilol170$1,908
Potassium Chloride62$1,320
Propafenone Hcl13$1,302
SotalolSotalol Hcl58$1,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$14$15,80218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →